Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060402 | 0.98 | DRD2 (0.48) | DRD2SLC6A4HTR1DHTR1BSCN9A | |
| SCHEMBL3352752 | 0.88 | HTR1B (0.57) | DRD2SLC6A4HTR1DHTR1BRORC | |
| SCHEMBL12127334 | 0.86 | SCN9A (0.52) | DRD2SLC6A4HTR1DHTR1BSCN9A | |
| SCHEMBL26630179 | 0.85 | DRD2 (0.48) | DRD2SLC6A4HTR1DHTR1BSCN9A | |
| SCHEMBL3351361 | 0.84 | DRD2 (0.50) | DRD2SLC6A4HTR1DHTR1BRORC | |
| SCHEMBL3355377 | 0.83 | DRD2 (0.62) | DRD2SLC6A4HTR1DHTR1BRORC | |
| SCHEMBL3348378 | 0.83 | DRD2 (0.49) | DRD2SLC6A4HTR1DHTR1BRORC | |
| SCHEMBL17495380 | 0.83 | RORC (0.64) | RORC | |
| SCHEMBL15712564 | 0.83 | DRD2 (0.50) | DRD2SLC6A4SCN9ASCN5ARORC | |
| Hydrochloric Acid SCHEMBL17495540 | 0.82 | RORC (0.63) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| CN-104870422-B | Amine derivative or its salt | 富士胶片富山化学株式会社 | 2019-03-15 | — | — | CN | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2915804-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-2915804-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2015-09-09 | — | — | EP | disclosed |
| CN-104870422-A | Novel amine derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2015-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | HRH4, CLIC4, KRT18 | DRD2 2201/4885SLC6A4 1980/4885HTR1D 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.